Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: rule (587), directive (20), parameter (132), instruction (834), ruling (587)

Quality account 24-25 final

Description: QUALITY ACCOUNT 2024/25 QUALITY ACCOUNT Contents Part 1: Statement on quality from the chief executive 1.1 Chief executive’s
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/quality-account-24-25-final1.pdf

Rituximab-Gemcitabine-Oxaliplatin (R-GemOx)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB-GEMCITABINE-OXALIPLATIN (R-GemOx) Regimen • Lymphoma – Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) Indication • Salvage regimen for relapsed/refractory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-Gemcitabine-Oxaliplatin-R-GemOx.pdf

Cyclophosphamide-Prednisolone-Rituximab- R-CP (21)

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB (R-CP) Regimen • Lymphoma – R-CP (21)-Cyclophosphamide-Prednisolone-Rituximab Indication • Lymphoplasmacytic lymphoma/Waldenstrom’s
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Prednisolone-Rituximab-R-CP-21.pdf

DRC-Cyclophosphamide-Dexamethasone-Rituximab

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE - DEXAMETHASONE – RITUXIMAB (DRC) Regimen • Lymphoma – DRC – Cyclophosphamide – Dexamethasone - Rituximab Indication • Lymphophlasmacytic lymphoma / Waldenstrom’s macroglobinaemia Toxicity Drug
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/DRC-Cyclophosphamide-Dexamethasone-Rituximab.pdf

Ipilimumab-Nivolumab

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB (3mg/kg)-NIVOLUMAB (1mg/kg) Regimen • Skin – Ipilimumab (3mg/kg)-Nivolumab (1mg/kg) Indication • Ipilimumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Ipilimumab-Nivolumab.pdf

Ipilimumab-Nivolumab Ver1

Description: Chemotherapy Protocol MESOTHELIOMA IPILIMUMAB-NIVOLUMAB Regimen • Mesothelioma – Ipilimumab-Nivolumab Indication • Nivolumab in combination with ipilimumab is indicated for the first-line
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/Ipilimumab-Nivolumab-Ver1.pdf

RFC_IV_Split

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (IV-Split) Regimen • CLL – RFC (IV)-Cyclophosphamide-Fludarabine-Rituximab (IV-Split) Indication • Chronic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-IV-Split.pdf

Chlorambucil_7_Rituximab_Split

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Chlorambucil (7 day)-Rituximab (Split) Regimen • CLL – Chlorambucil (7 day)-Rituximab (Split) Indication • Treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-7-Rituximab-Split.pdf

Bendamustine_90_RituximabSplit

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA BENDAMUSTINE (90)-RITUXIMAB (Split) There are multiple versions of this protocol in u
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Bendamustine-90-RituximabSplit.pdf

Bendamustine_70_RituximabSplit

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA BENDAMUSTINE (70)-RITUXIMAB (Split) This protocol may require funding There are multiple versions of this protocol
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Bendamustine-70-RituximabSplit.pdf

51 to 60 of 734

Previous … 4 5 6 7 8 … Next